Novartis says 330 jobs hit as it closes MorphoSys sites
Tweet
Share
E-mail
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) -Swiss pharmaceutical group Novartis said on Thursday it was winding up MorphoSys sites in Germany and the United States, affecting 330 jobs.
Novartis had acquired MorphoSys at the beginning of the year and said the move was part of an evaluation of its organisational setup and stemmed from its evolving research and development (R&D)
"We have communicated our intention to exit the MorphoSys sites in Munich and in Boston by end of 2025," a spokesperson said in an emailed statement to Reuters after a report in WirtschaftsWoche magazine.
"Approximately 330 roles were impacted, and all individuals were already communicated in mid-November," added the spokesperson, saying the company was committed to supporting the affected employees.
($1 = 0.9610 euros)
(Reporting by Paul Arnold, Writing by Friederike Heine and Madeline Chambers, Editing by Matthias Williams)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- European shares edge higher as bond yields ease
- Partner of Australian missing in Nepal presses tech firms for access to data
- Trump administration threatens to cut federal agencies' support for Smithsonian
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
